Table 1.

Clinicopathologic characteristics, follow-up, and outcomes of EXT-positive and EXT-negative SLE-MN

Variables	EXT+ n = 33	EXT− n = 53	P value
At presentation
Age, mean ± SD, yr	33.3 ± 12.9	39.9 ± 13.4	0.0267a
Female, n (%)	27 (81.8)	45 (84.9)	0.7061b
SCr, median (IQR), mg/dl	0.61 (0.50–0.87), n = 31	0.75 (0.60–1.00), n = 49	0.0546c
eGFR, mean ± SD, ml/min per 1.73 m2	122.6 ± 52.4, n = 31	95.5 ± 48.0, n = 49	0.0197a
Proteinuria, median (IQR), g/24 h	3.0 (1.4–4.6), n = 32	1.7 (0.9–3.3), n = 49	0.0334c
Proteinuria >3.0 g/24 h, n (%)	16 (50.0), n = 32	15 (30.6), n = 49	0.0793b
Hematuria, n (%)	8 (40.0), n = 20	18 (51.4), n = 35	0.4141b
Sclerosed glomeruli			0.0090b
<10%	30 (90.9)	35 (66.0)
≥10%	3 (9.1)	18 (34.0)
Interstitial fibrosis			0.0803b
Grade 0	28 (84.8)	36 (67.9)
Grade ≥1	5 (15.2)	17 (32.1)
Follow-up
Repeat biopsy	n = 26	n = 42	0.0189d
Class 3 or 4	2 (7.7)	15 (35.7)
Other	3 (11.5)	2 (4.8)
No renal biopsy	21 (80.8)	25 (59.5)
At end of follow-up
SCr, median (IQR), mg/dl	0.60 (0.55–0.72), n = 27	0.81 (0.68–0.93), n = 38	0.0017c
eGFR, mean ± SD, ml/min per 1.73 m2	114.6 ± 34.5, n = 27	84.6 ± 32.3, n = 38	0.0006a
Proteinuria, median (IQR), g/24 h	0.30 (0.11–0.60), n = 27	0.39 (0.20–1.36), n = 38	0.2413c
Proteinuria >3.0 g/24 h, n (%)	2 (7.4), n = 27	3 (7.9), n = 38	1.0000d
Clinical remission	n = 27	n = 38	0.0056b
Complete	19 (70.4)	21 (55.3)
Partial	7 (25.9)	5 (13.2)
No remission	1 (3.7)	12 (31.6)
Time of follow-up, median (IQR), mo	39.0 (22.0–79.0), n = 27	57.0 (27.0–75.0), n = 41	0.4620c

eGFR: estimated glomerular filtration rate; EXT, exostosin; IQR, interquartile range; SCr, serum creatinine; SLE-MN, systemic lupus erythematosus-associated membranous nephropathy.

Interstitial fibrosis grading is based on Banff classification.

^aStudent’s t test.

^bPearson’s chi-square test.

^cWilcoxon rank sum test.

^dFisher’s exact test.